ClinConnect ClinConnect Logo
Search / Trial NCT04680481

Non-Invasive Brain Stimulation to Control Large-Scale Brain Networks

Launched by UNIVERSITY OF MINNESOTA · Dec 17, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring a new method called traveling wave transcranial alternating current stimulation (tACS) to see if it can help improve working memory and brain connections in patients with epilepsy who are undergoing surgery. Working memory is the part of our brain that helps us hold and manipulate information, like remembering a phone number long enough to dial it. By using this non-invasive technique, researchers hope to find out if it can enhance brain function in a unique way.

To participate in this study, you must be at least 18 years old and capable of giving consent for yourself. You should either have or be scheduled to have electrodes implanted in your brain for evaluation related to epilepsy surgery. If you join, you can expect to undergo some tests and procedures to see how the tACS affects your working memory and brain activity. This trial is currently recruiting participants, and it aims to gather valuable information that could lead to new treatments for improving memory in individuals with epilepsy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. the patient can consent for themselves;
  • 2. the patient has or is scheduled for surgically implanted electrodes for the purposes of phase II epilepsy surgical evaluation;
  • 3. age 18+ years old;
  • Exclusion Criteria:
  • 1. diminished capacity to consent;

About University Of Minnesota

The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.

Locations

Minneapolis, Minnesota, United States

Patients applied

0 patients applied

Trial Officials

Alexander Opitz, PhD

Principal Investigator

University of Minnesota

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials